Table 2.
Summary of Acrometastasis Patient Characteristics Organized by Primary Cancer.
| Cancer groups | N value | Age, Mean, Y (range) | Male | Known history of malignancy | First diagnosis of primary cancer (prior mo)a | Other metastases before acrometastasis | Survival, mob |
|---|---|---|---|---|---|---|---|
| All patients | 592 | 59.45 (1.5-91) | 64.59% (374/579) | 65.35% (364/557) | 35.02 ± 50.78 (0.25-384), n = 315 | 37.80% (141/373) | 6.27 ± 7.16 (0.25-50), n = 310 |
| Lung | 232 | 60.24 (10-89) | 76.32% (174/228) | 42.27% (93/220) | 16.47 ± 37.09 (0.25-252), n = 74 | 18.60% (24/129) | 5.61 ± 6.62 (0.25-50), n = 135 |
| Oral | 15 | 62 (40-72) | 93.33% (14/15) | 92.86% (13/14) | 27.33 ± 21.70 (6-84), n = 12 | 54.55% (6/11) | 4.41 ± 4.87 (0.25- 14), n = 8 |
| Nasopharyngeal | 7 | 63.29 (45-80) | 85.71% (6/7) | 85.71% (6/7) | 59.17 ± 54.85 (12-160), n = 6 | 50.5% (3/6) | 10.93 ± 9.41 (1.7-24), n = 4 |
| Laryngeal | 10 | 59.6 (52-70) | 100% (10/10) | 100.0% (10/10) | 14.67 ± 8.47 (2-25), n = 9 | 11.11% (1/9%) | 5.19 ± 4.39 (1-14), n = 8 |
| Parotid | 5 | 58.5 (41-68) | 20.00% (1/5) | 100.0% (4/4) | 148 ± 184.48 (24-360), n = 3 | 100.0% (2/2) | 12 ± 0 (12-12), n = 1 |
| Thyroid | 9 | 54.89 (32-84) | 33.33% (3/9) | 55.56% (5/9) | 62.4 ± 24.59 (24-84), n = 5 | 28.57% (2/7) | 2.5 ± 0.71 (2-3), n = 2 |
| Breast | 47 | 55.16 (30-91) | 4.26% (2/47) | 95.35% (41/43) | 64.65 ± 74.74 (2-384), n = 39 | 59.38% (19/32) | 6.6 ± 8.44 (0.25-39), n = 24 |
| Liver | 12 | 56.42 (30-70) | 83.33% (10/12) | 58.33% (7/12) | 64.0 ± 60.97 (2-144), n = 6 | 62.5% (5/8) | 5.19 ± 4.54 (0.5-15), n = 8 |
| Esophageal | 30 | 62.43 (38-85) | 76.67% (23/30) | 83.33% (25/30) | 14.95 ± 21.44 (1-96), n = 21 | 42.11% (8/19) | 5.14 ± 5.92 (0.5-24), n = 14 |
| Gastric | 16 | 61.81 (37-84) | 62.5% (10/16) | 68.75% (11/16) | 20.45 ± 15.31 (2-48), n = 11 | 63.63% (7/11) | 9.88 ± 11.2 (3-36), n = 8 |
| Colorectal | 47 | 65.09 (38-84) | 55.56% (25/45) | 88.89% (40/45) | 34.06 ± 25.34 (4-120), n = 36 | 50.0% (15/30) | 8.93 ± 9.22 (1-39), n = 22 |
| Kidney | 64 | 62.31 (45-89) | 68.33% (41/60) | 68.97% (40/58) | 55.21 ± 68.87 (1-264), n = 34 | 45.0% (18/40) | 7.22 ± 6.04 (1-24), n = 29 |
| Bladder | 10 | 57.70 (39-72) | 80.0% (8/10) | 66.67% (6/9) | 41.00 ± 34 (7-96), n = 6 | 57.14% (4/7) | 2.75 ± 1.25 (1-4), n = 4 |
| Ovaries | 3 | 51.00 (43-59) | 0.0% (3/3) | 66.67% (2/3) | 8.5 ± 7.78 (3-14), n = 2 | 0.0% (0/3) | 1.63 ± 1.94 (0.25-3), n = 2 |
| Testes | 3 | 58.00 (55-63) | 100.0% (3/3) | 83.33% (5/6) | 3.33 ± 0.58 (3-4), n = 3 | 0.0% (0/3) | 3.5 ± 0.71 (3-4), n = 2 |
| Uterus | 7 | 49.86 (31-74) | 0.0% (0/7) | 83.33% (5/6) | 17.25 ± 13.94 (3-36), n = 4 | 50.0% (2/4) | 5.75 ± 4.65 (1-12), n = 4 |
| Prostate | 10 | 62.00 (50-76) | 100% (10/10) | 70.0% (7/10) | 27.5 ± 22.81 (7-60), n = 4 | 44.44% (4/9) | 13.17 ± 17.83 (2-48), n = 6 |
| Cervix/Vagina | 8 | 60.88 (36-85) | 0% (0/8) | 87.5% (7/8) | 5.71 ± 4.95 (0.5-12), n = 6 | 33.33% (2/6) | 5.42 ± 6.84 (0.5-19), n = 6 |
| Penile | 2 | 67.00 (63-71) | 100% (2/2) | 100.0% (2/2) | 15.0 ± 12.73 (6-24), n = 2 | 100% (1/1) | 18 ± 0 (18-18), n = 1 |
| Skeletal | 12 | 41.09 (9-76) | 72.73% (8/11) | 100.0% (11/11) | 38.6 ± 32.35 (12-120), n = 10 | 66.67% (6/9) | 4.95 ± 7.36 (0.25-18), n = 5 |
| Melanoma | 6 | 40.17 (24-65) | 16.67% (1/6) | 83.33% (5/6) | 34.2 ± 35.68 (5-96), n = 5 | 60.0% (3/5) | 13 ± 0 (13-13), n = 1 |
| Hematologic | 10 | 60.30 (40-72) | 30% (3/10) | 77.78% (7/9) | 41.0 ± 21.94 (6-72), n = 6 | 33.33% (2/6) | 3.34 ± 2.61 (0.36-6), n = 4 |
a
The values in this column are mean months between first diagnosis of primary to diagnosis of acrometastasis +/- SD (range), n value.
b
The values in this column are mean survival in months from the time of acrometastasis diagnosis +/- SD (range), n value.